Year: 2008
Type: letter
Abstract: P ϭ .0152).This finding is consistent with a previous study indicating that the clearance of paclitaxel was impaired in a patient with endstage renal failure, 15 similar to the findings with imatinib, 2 but not in an anephric patient on dialysis.16 The findings reported by Gibbons et al 2 support a growing body of evidence that renal failure can dramatically impact the pharmacokinetics of agents for which elimination is critically dependent on metabolism in the liver.Future studies should further evaluate the hypothesis that increased systemic concentrations of uremic toxins can directly inhibit the hepatic uptake of several anticancer agents, and that consideration of this type of interaction can guide the design and interpretation of dose-finding studies in patients with renal dysfunction.
Source: Journal of Clinical Oncology
Authors: Merrill Egorin, Ramesh K. Ramanathan, Joseph Gibbons, William Petros, S. Percy Ivy, Scot C. Remick
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: bronze
Funder: National Institutes of Health
Award: G9000113431
OpenAlex ID: W4250878996